203 related articles for article (PubMed ID: 18769895)
1. Recent advances in management of acute myeloid leukemia (AML).
Shah M; Agarwal B
Indian J Pediatr; 2008 Aug; 75(8):831-7. PubMed ID: 18769895
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy of acute myeloid leukemia in 2012: towards individualized therapy.
Foran JM
Hematology; 2012 Apr; 17 Suppl 1():S137-40. PubMed ID: 22507802
[TBL] [Abstract][Full Text] [Related]
3. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
4. Acute myelogenous leukemia: advances and limitations of treatment.
Parisi E; Draznin J; Stoopler E; Schuster SJ; Porter D; Sollecito TP
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Mar; 93(3):257-63. PubMed ID: 11925533
[TBL] [Abstract][Full Text] [Related]
5. Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study.
Lamba JK; Pounds S; Cao X; Downing JR; Campana D; Ribeiro RC; Pui CH; Rubnitz JE
Leukemia; 2009 Feb; 23(2):402-4. PubMed ID: 18615103
[TBL] [Abstract][Full Text] [Related]
6. CD33 as a target for selective ablation of acute myeloid leukemia.
Bernstein ID
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S9-11. PubMed ID: 11970770
[TBL] [Abstract][Full Text] [Related]
7. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
8. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
9. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
10. FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review.
Loschi M; Sammut R; Chiche E; Cluzeau T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070902
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib as a Salvage Therapy in FLT3-ITD Negative Relapse/ Refractory Acute Myeloid Leukemia.
Yang N; Gu Z; Liu Z; Huang W; Wang S; Wang L; Gao C
Anticancer Agents Med Chem; 2018; 18(10):1489-1494. PubMed ID: 29521250
[TBL] [Abstract][Full Text] [Related]
12. FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia.
Pollard JA; Alonzo TA; Gerbing RB; Woods WG; Lange BJ; Sweetser DA; Radich JP; Bernstein ID; Meshinchi S
Blood; 2006 Oct; 108(8):2764-9. PubMed ID: 16809615
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia.
Unal S; Cakir M; Kuşkonmaz B; Cetin M; Tuncer AM
Turk J Pediatr; 2009; 51(1):69-71. PubMed ID: 19378895
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
15. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
16. Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease.
Chevallier P; Robillard N; Ayari S; Guillaume T; Delaunay J; Mechinaud F; Avet-Loiseau H; Mohty M; Harousseau JL; Garand R
Br J Haematol; 2008 Dec; 143(5):744-6. PubMed ID: 19036018
[No Abstract] [Full Text] [Related]
17. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.
ten Cate B; Samplonius DF; Bijma T; de Leij LF; Helfrich W; Bremer E
Leukemia; 2007 Feb; 21(2):248-52. PubMed ID: 17122863
[TBL] [Abstract][Full Text] [Related]
18. Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment.
Yu MG; Zheng HY
Chin Med J (Engl); 2017 Jan; 130(2):211-218. PubMed ID: 28091414
[TBL] [Abstract][Full Text] [Related]
19. CD33-targeting extracellular vesicles deliver antisense oligonucleotides against FLT3-ITD and miR-125b for specific treatment of acute myeloid leukaemia.
Chen H; Jayasinghe MK; Yeo EYM; Wu Z; Pirisinu M; Usman WM; Pham TT; Lim KW; Tran NV; Leung AYH; Du X; Zhang Q; Phan AT; Le MTN
Cell Prolif; 2022 Sep; 55(9):e13255. PubMed ID: 35851970
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
